Barclays raises target for Givaudan stock to CHF 3,850.00

Published on 10/06/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Givaudan stock costs EUR 3,658.00 on October 6, 2026 after EUR 3,637.00, plus 0.58 percent. Barclays sees 5.60 percent third-quarter growth.

Givaudan CH0010645932 fotorealistisches Parfumeur-Atelier mit Reagenzgläsern, getrockneten Blüten und warmem goldenem Nachmittagslicht, Illustration mit AI erstellt.

Givaudan stock (ISIN CH0010645932) was trading at EUR 3,658.00 at Lang & Schwarz on October 6, 2026 at 2:16 p.m. CEST, plus 0.58 percent versus the prior close of EUR 3,637.00. On October 5, 2026, Barclays upgraded Givaudan from Equalweight to Overweight and raised its price target from CHF 3,450.00 to CHF 3,850.00, according to Investing.com.

Barclays sees stronger growth

The target increase reflects Barclays' view that Givaudan's Taste & Wellbeing division can recover after weaker performance. The bank forecasts group organic sales growth of 5.60 percent in the third quarter and 6.10 percent in the fourth quarter, while its 2026 forecast stands at 4.60 percent, Yahoo Finance reported on October 5, 2026.

Barclays also lifted its 2027 organic growth forecast to 5.80 percent from 5.00 percent and expects adjusted EBITDA of CHF 2.02 billion. The forecast is 5.00 percent above Bloomberg consensus, but the bank reduced its expected adjusted EBITDA margin to 23.90 percent from 24.20 percent because of raw-material cost pressure.

Results date adds a near-term test

Givaudan is scheduled to report third-quarter results on October 13, 2026. The same report says Barclays expects Taste & Wellbeing organic growth to reach 5.00 percent in 2027, compared with 4.50 percent previously, while Fine Fragrance growth is expected to return to double digits in the third quarter.

That outlook faces a measurable counterweight from Health & Functional, where Barclays estimates sales are falling 15.00 percent. Higher oil prices and agriculture-related inflation linked to El Nino could also pressure margins in 2027, making the October results a test of both volume recovery and pricing.

Givaudan combines growth with scale

For fiscal year 2025, Givaudan reported group sales of CHF 7.472 billion, up 5.10 percent on a like-for-like basis from 2024. Its official investor page lists a 23.40 percent EBITDA margin, CHF 1.751 billion in EBITDA, CHF 1.071 billion in net income and a CHF 72.00 dividend per share, Givaudan reports.

With a market capitalization of CHF 31.6 billion as of October 6, 2026, the company remains a large specialty chemicals issuer. Its two core divisions, Fragrance & Beauty and Taste & Wellbeing, leave the valuation especially sensitive to the recovery in food ingredients and continued demand for premium fragrances.

Stock price and investor view

At EUR 3,658.00, Givaudan stock was trading at Lang & Schwarz on October 6, 2026 at 2:16 p.m. CEST, up 0.58 percent from the EUR 3,637.00 prior close. The further course of trading is shown by the continuously updated real-time quote of Givaudan stock.